Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.77 |
| ▸ | GART known ✓ | P22102 | 10/20 | 0.57 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.57 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.57 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.57 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.57 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.57 |
| ▸ | ATIC | P31939 | 2/20 | 0.57 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.57 |
| ▸ | FRK | P42685 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL21599244 | 1.00 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2037608 | 1.00 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL135815 | 1.00 | TYMS (0.77) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL5333210 | 0.99 | TYMS (0.78) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1651788 | 0.99 | TYMS (0.78) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL18348 | 0.99 | TYMS (0.78) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15649196 | 0.97 | TYMS (0.75) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2268170 | 0.94 | TYMS (0.70) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL4987130 | 0.93 | TYMS (0.69) | TYMSGARTDHFRFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1271410 | 0.91 | TYMS (0.68) | TYMSGARTDHFRFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11759445-B2 | Use of Rivastigmine in preparation of anti-radiation medicament | SOOCHOW UNIVERSITY (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-109906071-A | Intravenous infusion dosage forms of pemetrexed | 太阳制药工业公司 | 2019-06-18 | — | — | CN | disclosed |
| US-9174991-B2 | Crystalline form of pemetrexed disodium | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-8629152-B2 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | SICOR, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | UNIVERSITY OF ZURICH (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-2504341-A1 | A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | Azad Pharmaceutical Ingredients AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064256-A1 | A NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| EP-1943252-B1 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | SICOR INC (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1943252-A2 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | Sicor, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2008-06-12 | — | — | US | disclosed |
| WO-2008021411-A2 | PROCESSES FOR THE PREPARATION OF LYOPHILIZED PHARMACEUTICALLY ACCEPTABLE SALTS OF PEMETREXED DIACID | SICOR INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329819-A1 | NEW CRYSTALLINE FORM OF PEMETREXED DISODIUM | TYMP, TYMS, MTHFD1 | TYMS 2/4885GART 149/4885DHFR 11/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | TYMS 1661/4885GART 4268/4885DHFR 503/4885 |
| US-20080139810-A1 | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid | DCTD, DPYD, PDCD2L | TYMS 7/4885GART 77/4885DHFR 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.